Journal: bioRxiv

Article Title: ERBB4-mediated signaling is a mediator of resistance to BTK and PI3K inhibitors in B cell lymphoid neoplasms

doi: 10.1101/2023.01.01.522017

Figure Lengend Snippet: (A) Expression of surface ERBB4 by FACS in parental (grey) and resistant (red) lines. Dashed black line for negative control (neg-cnt). Data derived from two independent experiments. (B) Secretion of HBEGF in parental (grey) and resistant (red) by ELISA. Data derived from three independent experiments. (C) Expression levels of surface CD19 (x-axis, PE-conjugated) and intracellular HBEGF (y-axis, APC-conjugated) by FACS in parental (left) and resistant (right) cells, percentage correspond to percentages of total viable cells. Data representative of two independent experiments. (D) Levels of protein phosphorylation by immunoblot in parental (grey) and resistant (red) cells. Values correspond to average of protein quantification normalized to GAPDH levels in three independent experiments. Error bars represent standard error of the mean. (E) Quantification of AKT phosphorylation by immunofluorescence, error bars represent standard error of the mean. Data derived from at least three independent experiments. P values from t-test, statistically significant for p< 0.05. (E) Detail of p-AKT expression by immunofluorescence in parental (PAR, top) and resistant (RES, bottom) upon DMSO (control, left) or 1μM idelalisib (right). (G) Cell viability by MTT assay of parental cells (PAR, black line) exposed to idelalisib in presence or not of conditioned medium from Karpas1718 idelalisib-resistant (RES, red line), cultured for 48h, PAR + RES-cond RPMI, dashed black line) or stimulated with 30ng/ml of recombinant HBEGF (dashed red line). Data derived from the average of three independent experiments. P values from a moderated t-test, statistically significant for p< 0.05.

Article Snippet: ELISA (Human HB-EGF Quantikine ELISA Kit, R&D Systems) was performed according to the manufacturer’s protocols.

Techniques: Expressing, Negative Control, Derivative Assay, Enzyme-linked Immunosorbent Assay, Phospho-proteomics, Western Blot, Immunofluorescence, Control, MTT Assay, Cell Culture, Recombinant

Journal: bioRxiv

Article Title: ERBB4-mediated signaling is a mediator of resistance to BTK and PI3K inhibitors in B cell lymphoid neoplasms

doi: 10.1101/2023.01.01.522017

Figure Lengend Snippet: (A) Small interfering RNAs were used for gene expression silencing of ERBB2 alone (yellow dashed line), ERBB4 alone (red dashed line) or concomitant silencing of ERBB2 and ERBB4 (brown dashed line). Black lines for resistant control. (B) miRNAs mimics were used for miR-29c expression (yellow dashed line), let-7c (red dashed line) or miR-30c (brown dashed line). Black lines for resistant control. Drug sensitivity was evaluated by MTT assay in resistant Karpas1718 cells for the PI3K inhibitors idelalisib, umbralisib, copanlisib and duvelisib. Data correspond of two independent experiments, error bars represent standard deviation of the mean. P values from a moderated t-test, statistically significant for p< 0.05. (C) Levels of HBEGF secretion by ELISA in resistant cells upon miRNA mimics for miR-29c (yellow), let-7c (red) or control (grey). Data derived from three independent experiments. P values from a moderated t-test, statistically significant for p< 0.05.

Article Snippet: ELISA (Human HB-EGF Quantikine ELISA Kit, R&D Systems) was performed according to the manufacturer’s protocols.

Techniques: Gene Expression, Control, Expressing, MTT Assay, Standard Deviation, Enzyme-linked Immunosorbent Assay, Derivative Assay

Journal: bioRxiv

Article Title: ERBB4-mediated signaling is a mediator of resistance to BTK and PI3K inhibitors in B cell lymphoid neoplasms

doi: 10.1101/2023.01.01.522017

Figure Lengend Snippet: (A) HBEGF secretion was evaluated in the serum of CLL samples at the end of the treatment by ELISA (Luminex, R&D Systems). (A) Patients responding (responders, blue) or non-responding (non-responders, red) to idelalisib were compared by t-test. (B) HBEGF secretion in the serum of patients treated with ibrutinib was compared at the time of progression (red) with baseline levels previously of ibrutinib treatment (pre-treatment, blue). P for adjusted p-value from a t-test. MFI: mean fluorescence intensity.

Article Snippet: ELISA (Human HB-EGF Quantikine ELISA Kit, R&D Systems) was performed according to the manufacturer’s protocols.

Techniques: Enzyme-linked Immunosorbent Assay, Luminex, Fluorescence

Journal: Journal of Clinical Medicine

Article Title: Serum Concentration of Selected Angiogenesis-Related Molecules Differs among Molecular Subtypes, Body Mass Index and Menopausal Status in Breast Cancer Patients

doi: 10.3390/jcm11144079

Figure Lengend Snippet: Median concentrations (interquartile range) of VEGF, HB-EGF, PDGF-CC and NRP-1 in the serum of the examined patients and healthy women.

Article Snippet: Serum levels of VEGF, HB-EGF, PDGF-CC and NRP-1 were quantified using an Enzyme-linked immunosorbent assay (Elisa) with the respective Human VEGF, HB-EGF, PDGF-CC and NRP-1 Quantikine ® ELISA kits (R&D Systems, Minneapolis, MN, USA) used according to the manufacturer’s instructions.

Techniques:

Journal: Journal of Clinical Medicine

Article Title: Serum Concentration of Selected Angiogenesis-Related Molecules Differs among Molecular Subtypes, Body Mass Index and Menopausal Status in Breast Cancer Patients

doi: 10.3390/jcm11144079

Figure Lengend Snippet: Median concentrations of VEGF, HB-EGF, PDGF-CC and NRP-1 in the serum of the examined patients considering breast cancer molecular subtypes.

Article Snippet: Serum levels of VEGF, HB-EGF, PDGF-CC and NRP-1 were quantified using an Enzyme-linked immunosorbent assay (Elisa) with the respective Human VEGF, HB-EGF, PDGF-CC and NRP-1 Quantikine ® ELISA kits (R&D Systems, Minneapolis, MN, USA) used according to the manufacturer’s instructions.

Techniques:

Journal: Journal of Clinical Medicine

Article Title: Serum Concentration of Selected Angiogenesis-Related Molecules Differs among Molecular Subtypes, Body Mass Index and Menopausal Status in Breast Cancer Patients

doi: 10.3390/jcm11144079

Figure Lengend Snippet: Correlation of VEGF, HB-EGF, PDGF-CC and neuropilin-1 expression levels with tumor grade and stage of disease.

Article Snippet: Serum levels of VEGF, HB-EGF, PDGF-CC and NRP-1 were quantified using an Enzyme-linked immunosorbent assay (Elisa) with the respective Human VEGF, HB-EGF, PDGF-CC and NRP-1 Quantikine ® ELISA kits (R&D Systems, Minneapolis, MN, USA) used according to the manufacturer’s instructions.

Techniques: Expressing

Journal: Journal of Clinical Medicine

Article Title: Serum Concentration of Selected Angiogenesis-Related Molecules Differs among Molecular Subtypes, Body Mass Index and Menopausal Status in Breast Cancer Patients

doi: 10.3390/jcm11144079

Figure Lengend Snippet: Differences in molecule levels considering BMI values and histological types/molecular subtypes of breast cancer.

Article Snippet: Serum levels of VEGF, HB-EGF, PDGF-CC and NRP-1 were quantified using an Enzyme-linked immunosorbent assay (Elisa) with the respective Human VEGF, HB-EGF, PDGF-CC and NRP-1 Quantikine ® ELISA kits (R&D Systems, Minneapolis, MN, USA) used according to the manufacturer’s instructions.

Techniques:

Journal: Journal of Clinical Medicine

Article Title: Serum Concentration of Selected Angiogenesis-Related Molecules Differs among Molecular Subtypes, Body Mass Index and Menopausal Status in Breast Cancer Patients

doi: 10.3390/jcm11144079

Figure Lengend Snippet: Box plots of VEGF and HB-EGF serum levels according to the BMI status of patients with breast cancer.

Article Snippet: Serum levels of VEGF, HB-EGF, PDGF-CC and NRP-1 were quantified using an Enzyme-linked immunosorbent assay (Elisa) with the respective Human VEGF, HB-EGF, PDGF-CC and NRP-1 Quantikine ® ELISA kits (R&D Systems, Minneapolis, MN, USA) used according to the manufacturer’s instructions.

Techniques:

Journal: Journal of Clinical Medicine

Article Title: Serum Concentration of Selected Angiogenesis-Related Molecules Differs among Molecular Subtypes, Body Mass Index and Menopausal Status in Breast Cancer Patients

doi: 10.3390/jcm11144079

Figure Lengend Snippet: Box plots of VEGF, HB-EGF, PDGF-CC and NRP-1 serum levels among patients with different molecular subtypes according to their BMI status.

Article Snippet: Serum levels of VEGF, HB-EGF, PDGF-CC and NRP-1 were quantified using an Enzyme-linked immunosorbent assay (Elisa) with the respective Human VEGF, HB-EGF, PDGF-CC and NRP-1 Quantikine ® ELISA kits (R&D Systems, Minneapolis, MN, USA) used according to the manufacturer’s instructions.

Techniques:

Journal: Journal of Clinical Medicine

Article Title: Serum Concentration of Selected Angiogenesis-Related Molecules Differs among Molecular Subtypes, Body Mass Index and Menopausal Status in Breast Cancer Patients

doi: 10.3390/jcm11144079

Figure Lengend Snippet: The median concentrations (interquartile range) of the examined molecules in premenopausal and postmenopausal women.

Article Snippet: Serum levels of VEGF, HB-EGF, PDGF-CC and NRP-1 were quantified using an Enzyme-linked immunosorbent assay (Elisa) with the respective Human VEGF, HB-EGF, PDGF-CC and NRP-1 Quantikine ® ELISA kits (R&D Systems, Minneapolis, MN, USA) used according to the manufacturer’s instructions.

Techniques:

Journal: Journal of Clinical Medicine

Article Title: Serum Concentration of Selected Angiogenesis-Related Molecules Differs among Molecular Subtypes, Body Mass Index and Menopausal Status in Breast Cancer Patients

doi: 10.3390/jcm11144079

Figure Lengend Snippet: p values were determined in order to investigate the differences in protein levels between breast cancer histological types and control group as well as among the different histological types when considering the menopausal status of the examined women.

Article Snippet: Serum levels of VEGF, HB-EGF, PDGF-CC and NRP-1 were quantified using an Enzyme-linked immunosorbent assay (Elisa) with the respective Human VEGF, HB-EGF, PDGF-CC and NRP-1 Quantikine ® ELISA kits (R&D Systems, Minneapolis, MN, USA) used according to the manufacturer’s instructions.

Techniques: Control

Journal: World Journal of Gastroenterology

Article Title: Forkhead Box q1 promotes invasion and metastasis in colorectal cancer by activating the epidermal growth factor receptor pathway

doi: 10.3748/wjg.v28.i17.1781

Figure Lengend Snippet: Effect of forkhead Box q1 expression on heparin binding epidermal growth factor expression and extracellular release ability in colorectal cancer cells. A: Quantitative analysis of western blots was performed to detect the expression of heparin binding epidermal growth factor (HB-EGF) with forkhead Box q1 (FOXQ1) inhibition; B: Flow cytometry was performed to detect the effect of changes in FOXQ1 expression on the expression of proHB-EGF in DLD1 and SW480 cells; C: ELISA verified the effect of FOXQ1 knockdown on sHB-EGF expression in DLD1 and SW480 cells; D: ELISA confirmed the effect of FOXQ1 on the expression of proHB-EGF extracellular release proteins (ADAM9, ADAM10, ADAM12 and MMP-7) in DLD1 and SW480 cells. a P < 0.05; b P < 0.01; c P < 0.001. FOXQ1: Forkhead Box q1; HB-EGF: Heparin binding epidermal growth factor; ProHB-EGF: Membrane-bound HB-EGF; SHB-EGF: Souble HB-EGF; ADAM9: A disintegrin and a metalloprotease 9; ADAM10: A disintegrin and a metalloprotease 10; ADAM12: A disintegrin and a metalloprotease 12; MMP7: Matrix metallopeptidase 7.

Article Snippet: The supernatant was collected after the cells were cultured for another 24 h. The protein concentrations of soluble HB-EGF, ADAM9, ADAM10, ADAM12 and MMP-7 in the cell culture medium were determined by ELISA detection kits against human HB-EGF, ADAM9, ADAM10, ADAM12 and MMP-7, respectively (R&D Systems, Minneapolis, United States).

Techniques: Expressing, Binding Assay, Western Blot, Inhibition, Flow Cytometry, Enzyme-linked Immunosorbent Assay, Knockdown, Membrane